Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Commercial Assay Aids Physicians in Tamoxifen Drug Monitoring

By LabMedica International staff writers
Posted on 30 Dec 2015
A laboratory developed test could help assess levels of several tamoxifen drug metabolites in a blood specimen which is important as five years of therapy with tamoxifen has been the standard of care for women with early stage, estrogen-receptor-positive (ER+) breast cancer following "curative" surgery. More...


Tamoxifen, taken for five years, reduces the risk of developing invasive breast cancer by about 50% in postmenopausal women who are at increased risk of getting the disease. However, compliance is an issue and patients could be further helped from precise prescribing as side effects from Tamoxifen are known to include mood swings, depression, and loss of libido, cataracts, blood clots, strokes, bone loss and the increase risk of endometrial and uterine cancer.

Medical experts from Quest Diagnostics (Madison, NJ, USA) show how the laboratory developed test could help assess levels of several tamoxifen drug metabolites in a blood specimen. The scientists evaluated the blood serum from 155 women who were on 20 mg/day tamoxifen for more than six months. The patient population exhibited a wide range of concentrations of tamoxifen and its metabolites during therapy, reflecting individual differences in the ability to metabolize the drug.

The test is based on a tandem mass spectrometry, (LC-MS/MS) a technique used by world-class laboratories to measure hormones and vitamin D, the test allows physicians, for the first time, to employ a commercially available therapeutic drug monitoring approach for their tamoxifen-treated patients. The test may also help physicians assess noncompliance with tamoxifen therapy, a common problem given side effects such as weight gain or loss.

Nigel Clarke, PhD, coauthor and a senior scientific expert responsible for technology innovation for Quest Diagnostics, said, “When people think of personalized medicine or precision medicine they often think of genetic testing to assess a drug against a gene variant. But a growing area in personalized medicine is the use of qualitative enzyme or drug metabolite testing to assess the biological impact of a drug rather than the indirect influence of genes.” The study was presented on December 11, 2015, at the San Antonio Breast Cancer Symposium held in San Antonio (TX, USA).

Related Links:

Quest Diagnostics  



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.